Benlysta® (belimumab) – New formulation approval
July 21, 2017 – GlaxoSmithKline announced the FDA approval of Benlysta (belimumab) injection, for subcutaneous (SC) use, for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.
Top